Minaris: Simplifying the Path from Development to Commercial Supply
Minaris is a global CDMO and biosafety testing partner advancing the next generation of cell and gene therapies and biologics. Headquartered in Philadelphia, Pennsylvania, the company works with biotech, pharma, and advanced therapy developers across manufacturing, testing, and commercialization, helping bring life-changing therapies to patients faster and at scale. This Spotlight looks at what Minaris does, what sets its approach apart, a recent program the team is proud of, and where clients see the field heading next.
July 15, 2026
The Spotlight
Q1. What does Minaris do, and who does it serve?
Minaris is a global cell and gene therapy (CGT) CDMO and advanced testing partner, supporting biotech, pharmaceutical, and cell and gene therapy companies from development through commercialization. Through our two business units, Minaris Advanced Therapies and Minaris Advanced Testing, we provide manufacturing, process and analytical development, and biosafety testing services across a range of biologics modalities.
While our direct customers are therapy developers, the ultimate beneficiary of our work is the patient. Every manufacturing run, testing program, and commercialization strategy is designed to help bring safe, effective therapies to the people who need them.
Companies developing advanced therapies often need support across manufacturing, testing, and commercialization. By bringing these capabilities together under one organization, Minaris helps streamline development, reduce complexity, and accelerate progress toward the clinic and commercial supply — letting innovators stay focused on advancing therapies for patients.
Q2. What sets Minaris's approach apart?
Our differentiation comes from combining scientific expertise, commercial manufacturing experience, integrated manufacturing and testing capabilities, and a highly collaborative approach with our customers.
Many organizations support only individual stages of development, but Minaris can support everything from plasmid engineering and viral vector manufacturing to cell therapy manufacturing and release testing. That means customers work with one team that understands the full process, rather than managing multiple vendors across critical activities.
Our model is built on integrating our Advanced Therapies CDMO capabilities with our Advanced Testing services. Minaris Advanced Therapies supports the development and production of cell and gene therapies, while Minaris Advanced Testing provides GMP biosafety and analytical testing across these modalities and biologics. Bringing these together helps customers reduce coordination challenges, maintain continuity across development and commercialization, and generate the data needed to support regulatory submissions and product release.
We also have teams across our global network with direct experience bringing cell therapies to market, and we know approval isn't the finish line. Once a therapy reaches market, companies face new challenges around supply, scale, and regulatory requirements. Our teams have experience helping customers navigate that phase and prepare for long-term growth.
Q3. What is a recent project, engagement, or result Minaris is particularly proud of?
One area we're particularly proud of is our work supporting commercial cell therapy manufacturing programs.
As more advanced therapies reach commercialization, the focus shifts from clinical manufacturing to reliable commercial supply, growing demand, and long-term operational execution. One example is our work supporting commercial manufacturing of LYFGENIA™, where our team in Allendale, New Jersey, helps sustain ongoing production as the therapy reaches patients.
This work reflects a broader shift across the industry: more therapies are reaching commercialization, and companies need partners who can support them beyond approval. As demand grows and regulatory requirements evolve, having a CDMO partner with the experience, infrastructure, and testing capabilities to scale alongside a program becomes increasingly important.
Supporting companies through that transition is an area where Minaris has significant experience, and it's work we're proud of because it helps ensure therapies remain available to the patients who depend on them.
Q4. Which Big4Bio regions does Minaris serve, and which is it particularly focused on right now?
Minaris serves customers across the globe, including all of the major life sciences hubs Big4Bio covers.
Philadelphia plays an especially important role for us as the location of our U.S. headquarters, which is home to one of our commercial manufacturing facilities and our Advanced Testing center of excellence. The region continues to grow as a hub for cell and gene therapy innovation, with strong academic institutions, clinical research organizations, and emerging biotech companies.
While our operations span multiple regions and countries, our focus stays the same: helping clients navigate the manufacturing and testing challenges that come with bringing therapies to patients.
Q5. What trend or challenge in life sciences are Minaris's clients asking about most right now?
One of the biggest challenges we hear about is complexity.
Companies today are developing a wider range of modalities than ever before, from biologics and viral vectors to cell and gene therapies. As programs advance, teams often find themselves managing multiple vendors, evolving regulatory requirements, and increasingly complex testing and manufacturing strategies.
Customers are looking for partners with the experience to help them make informed decisions early — whether that's selecting the right manufacturing approach, planning a testing strategy, or thinking through regulatory expectations — so they can avoid delays and unnecessary rework later.
We're also seeing growing interest in more integrated solutions. Rather than coordinating separate vendors for plasmids, viral vectors, cell therapy manufacturing, and testing, many companies want to simplify how they work. Bringing those capabilities together can improve communication, reduce handoffs, and help teams stay focused on advancing their programs.
For our testing business specifically, customers consistently tell us they value reliability and consistency: accurate, regulator-ready data delivered on time, so they can make decisions and keep programs moving forward.
About The Organization
Minaris
Minaris is a global CDMO and biosafety testing partner advancing the next generation of cell and gene therapies and biologics. With decades of experience across CGT manufacturing and GMP biosafety and analytical testing, the company pairs deep scientific expertise with a unified model built to simplify complex development pathways. Operating across global manufacturing sites and a centralized testing center of excellence, Minaris supports innovators from early development through commercial supply, with a focus on quality, execution, and partnership. Its mission is to help life-changing therapies reach patients faster, safely, and at scale.